Comparing SG&A Expenses: Dr. Reddy's Laboratories Limited vs Lantheus Holdings, Inc. Trends and Insights

SG&A Expenses: Dr. Reddy's vs. Lantheus - A Decade of Growth

__timestampDr. Reddy's Laboratories LimitedLantheus Holdings, Inc.
Wednesday, January 1, 20143878300000072429000
Thursday, January 1, 20154258500000078634000
Friday, January 1, 20164570200000075374000
Sunday, January 1, 20174637200000092157000
Monday, January 1, 20184691000000093326000
Tuesday, January 1, 201948890000000103132000
Wednesday, January 1, 202050129000000110171000
Friday, January 1, 202154559000000218817000
Saturday, January 1, 202262081000000233827000
Sunday, January 1, 2023105931000000267194000
Monday, January 1, 202477201000000
Loading chart...

Infusing magic into the data realm

A Tale of Two Companies: SG&A Expenses Over Time

In the ever-evolving pharmaceutical and healthcare landscape, understanding the financial dynamics of key players is crucial. Dr. Reddy's Laboratories Limited, a prominent name in the pharmaceutical industry, has shown a remarkable increase in its Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Dr. Reddy's SG&A expenses surged by approximately 173%, peaking in 2023. This growth reflects the company's expanding operations and strategic investments.

In contrast, Lantheus Holdings, Inc., a leader in diagnostic imaging, has maintained a more modest trajectory. Their SG&A expenses grew by about 269% from 2014 to 2023, indicating a steady yet significant expansion. However, data for 2024 is missing, leaving room for speculation on future trends.

This comparison highlights the diverse strategies and growth patterns of these two industry giants, offering valuable insights for investors and analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025